Novocure (NVCR) announced it submitted a premarket approval application to the FDA for Tumor Treating Fields therapy for the treatment of locally advanced pancreatic cancer. Novocure anticipates an approval decision in the second half of 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- NovoCure’s Pivotal Study on Optune® for Glioblastoma: A Market Game-Changer?
- Novocure’s Earnings Call: Clinical Successes & Cautious Optimism
- Positive Outlook for NovoCure: Strong Financial Performance and Promising Pipeline Developments
- Novocure Ltd. Reports Q2 2025 Financial Results
- Wells Fargo downgrades Novocure after ‘disappointing’ Q2